Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, single-center, single-arm phase II clinical trial evaluating the
combination of pembrolizumab, binimetinib, and bevacizumab in patients with metastatic
colorectal adenocarcinoma who have not responded to prior therapy.